Led by a former tobacco company executive, Qnovia looks to offer nicotine replacement therapy through inhaled drug delivery. Brian Quigley spent just over 16 years at tobacco giant Altria. During his time there, he ran two U.S. business units, including the smokeless tobacco business. In July 2020, he joined founder and then-CEO at Qnovia (then […]
Respiratory
Qnovia raises $17M Series A for inhaled therapeutics pipeline
Qnovia announced today that it raised $17 million in a Series A financing to support its inhaled therapeutics technologies. Blue Ledge Capital led the offering. DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures also participated. Los Angeles-based Qnovia develops inhaled therapeutics. It focuses on nicotine replacement therapy (NRT) and cardiopulmonary diseases. Qnovia […]
Philip Morris hires two former FDA officials as it pushes ‘smoke-free’ development
Cigarette maker Philip Morris (NYSE:PM) announced today that it appointed two former FDA officials to leadership positions. Dr. Badrul Chowdhury is the company’s new chief life sciences officer for smoke-free products. Dr. Matthew Holman joins as VP of U.S. scientific engagement and regulatory strategy. Both appointments fall in line with the company’s efforts to push […]
Lyra Therapeutics enrolls first patient in Phase 3 chronic rhinosinusitis trial
Lyra Therapeutics (Nasdaq:LYRA) announced today that it enrolled the first patient in its Phase 3 Enlighten II clinical trial. Enlighten II is evaluating the company’s LYR-210 in adult patients with chronic rhinosinusitis (CRS). Lyra’s proprietary XTreo platform delivers LYR-210. Watertown, Massachusetts-based Lyra designed the proprietary XTreo platform for precise, sustained and local delivery. The platform […]
Study backs RejuvenAir treatment for bronchitis from CSA Medical
CSA Medical announced today that study data support the use of its RejuvenAir system for treating chronic bronchitis. Boston-based CSA Medical designed its metered cryospray (MCS) treatment using the RejuvenAir System. RejuvenAir, a proprietary interventional liquid nitrogen spray cryotherapy system, utilize software-driven dosimetry and specialty catheter. Together, this enables the delivery of cryogen spray inside […]
Aptar acquires Orbital dry powder inhaler license
Aptar Pharma announced today that it acquired the worldwide writes to Pharmaxis’ proprietary Orbital inhaler. Pharmaxis designed its Orbital technology to deliver high-payload dry powder to the lungs, helping to meet the need to deliver high doses of drugs such as antibiotics. According to a news release, the Orbital inhaler allows payloads of up to […]
Here’s what some drug delivery devices look like on a CT scan
If you’ve ever wondered what the inside of some impressive drug delivery technology innovations looks like, look no further. ScanOfTheMonth.com publishes monthly collections of CT scans of exciting products and the month of July has some intriguing scans of drug delivery devices, including inhalers, pens and more. The scans cover life-saving technologies that span the […]
Lyra Therapeutics appoints new chief medical officer
Lyra Therapeutics (Nasdaq:LYRA) announced today that it appointed Dr. Richard Nieman as its new chief medical officer (CMO). Nieman’s appointment as CMO of Lyra, which develops the XTreo — a platform for enabling precise, sustained and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues — will be […]
Lyra Therapeutics closes $100.5M private placement
Lyra Therapeutics (Nasdaq:LYRA) announced today that it closed its previously announced private placement worth $100.5 million. The company announced last week that, in the private placement, investors had the option in the private placement to purchase either shares of Lyra’s common stock at $4.22 per share or, in lieu thereof, pre-funded warrants to purchase shares […]
Lyra Therapeutics announces $100.5M private placement
Lyra Therapeutics (Nasdaq:LYRA) announced today that it agreed to sell securities in a private placement worth more than $100 million. The company — which develops the XTreo platform designed to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues — did not list an […]
